ligelizumab
Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria
January 9, 2020Research and Development Novartis, Xolair, ligelizumab
Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
